J. Garcia‐Vargas

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 398 citations

Medicine, Oncology, Pharmacology +13

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

M. Dreyling, Franck Morschhauser, Krimo Bouabdallah et al. · Annals of Oncology · 2017 · 272 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · American Journal of Hematology · 2019 · 172 citations · Full text

Medicine, Oncology, Pharmacology +12

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan et al. · European Journal of Cancer · 2011 · 137 citations

Medicine, Oncology, Radiation Oncology +17